Madrigal Pharmaceuticals (MDGL) Stock May Be Below Fair Value Despite First Profit

Madrigal Pharmaceuticals has gone from a relatively small specialist to a business with more than US$1b in annualised sales from its liver drug Rezdiffra, yet the share price has…

MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (finance.yahoo.com)